Clinical Trials Directory

Trials / Completed

CompletedNCT06461325

Surgical Management Of Gastroschisis

Surgical Management Of Gastroschisis With Analysis Of Health Costs And Satisfaction Questionnaire On The Quality Of The Scar: A Retrospective Single-Center Comparative Study

Status
Completed
Phase
Study type
Observational
Enrollment
30 (actual)
Sponsor
University Hospital, Clermont-Ferrand · Academic / Other
Sex
All
Age
1 Minute – 17 Years
Healthy volunteers
Not accepted

Summary

The investigators aim to analyze the management of children born with gastroschisis between January 2009 and December 2023, i.e. to evaluate post-operative follow-up, hospitalization costs, the risk of post-operative umbilical hernia, and the parents' and the child's appreciation of the scar.

Detailed description

Gastroschisis is an abdominal wall anomaly that affects 3 in 10,000 live births, and in over 90% of cases is diagnosed before birth. In fetuses with gastroschisis, the intestine protrudes through a defect in the abdominal wall, usually to the right of the umbilical cord. Although the survival rate of live newborns with gastroschisis is over 90%, the risk of intrauterine fetal death is still 7.5 times higher than in the normal population, and gastroschisis can cause significant morbidity during the neonatal period. The scientific literature suggests multiple options for each stage in the care of children with gastroschisis, both pre- and postnatally. Heterogeneity of practice exists even within the same geographical area, and deserves to be analyzed. In this context, the investigators wish to analyze the management of children born with gastroschisis between January 2009 and December 2023, i.e. to evaluate post-operative follow-up, hospitalization costs, the risk of post-operative umbilical hernia, and the parents' and the child's appreciation of the scar.

Conditions

Timeline

Start date
2024-05-01
Primary completion
2024-08-27
Completion
2024-08-28
First posted
2024-06-17
Last updated
2024-08-28

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT06461325. Inclusion in this directory is not an endorsement.